Clinical Oncology Next Generation Sequencing Market Size, Share & Growth Report, 2033
The global clinical oncology next generation sequencing market size was estimated at USD 787.91 million in 2023 and is projected to hit around USD 3,232.18 million by 2033, growing at a CAGR of 15.16% during the forecast period from 2024 to 2033.
Key Takeaways:
Clinical Oncology Next Generation Sequencing Market Growth
The key drivers responsible for clinical oncology next-generation Sequencing (NGS) market growth are increasing technological advancements, growing competition among players, increasing healthcare spending, and the rise in the prevalence of cancer. In addition, augmenting research & development activities to invent solutions is expected to fuel market growth over the forecast period. The COVID-19 pandemic has significantly impacted the market. The regulations and guidelines mandated by various countries' governments for cancer treatment have fueled the market during the pandemic. For instance, the Scottish Government's National Cancer Treatment Response Group allowed continuing essential cancer treatment by altering the treatment pathways in December 2020.
Moreover, the NGS diagnostic technology has the potential edge to determine a virus's genetic sequence and enables scientists to understand the mutations. During the COVID-19 pandemic, private players and government authorities worked to bring NGS technology as a diagnostic tool into the market. For instance, the U.S. Centers for Medicare & Medicaid Services expanded coverage of FDA-approved laboratory diagnostic tests using NGS in January 2020 for breast or ovarian cancer patients. These factors pushed the market demand during COVID-19 pandemic.
The increase in clinical applications of NGS in precision oncology has compelled key companies to invent novel platforms that can be utilized for genomic insights. For instance, in August 2022, Thermo Fisher Scientific, a key player in the market, introduced NGS Analysis and Test Software CE-IVD (IVDD) to extend access to precision oncology biomarker testing. This software enables healthcare providers to evaluate genomic test results quickly. The software compares the variant data to relevant evidence, including supported guidelines, therapies, clinical trials, and peer-reviewed literature. Such inventions in clinical applications of NGS can augment the market demand.
Moreover, the rising prevalence of cancer worldwide is the prominent factor driving the market. According to the article published by WebMD in June 2022, every year, more than 600,000 deaths are caused by cancer in the U.S. and around 80,000 in Canada. In addition, the International Agency for Research on Cancer (IARC) estimated nearly 27.5 million new cancer cases by 2040. NGS is useful for identifying rare and novel cancer mutations, detecting familial cancer mutation carriers, and giving a molecular rationale for suitable targeted treatment. As a result, it is projected that the increase in cancer incidences across the world can propel the demand for clinical oncology in next generation sequencing market.
Technological advancements in next-generation sequencing (NGS) and the growing adoption of companion diagnostics and personalized medicine are expected to propel market growth. Moreover, the rising usage of NGS for liquid biopsy is anticipated to drive revenue generation. The technological advances in NGS are useful in sequencing circulating tumor DNA for liquid biopsy sample analysis, which helps in effectively profiling cancers and facilitating real-time, non-invasive monitoring of cancer.
In addition, increasing market competition and the rising research & development activities to invent solutions can boost market demand. For instance, in May 2022, Berry Oncology, a company of early screening and genetic testing of tumors, introduced HIFI System, a novel self-iterative liquid biopsy technology. This technology enables early screening for cancer and delivers timely treatment to patients.
Next-generation technology facilitates cost- and time-effective sequencing of cancer DNA, transforming cancer treatment research. The wide application of NGS and bioinformatics tools can revolutionize cancer research, diagnosis, and therapy.NGS is an advanced technology that has rapidly developed. The adoption of NGS technology, particularly in the cancer field, regarding the genetic aspects of the disorder, is anticipated to influence the market growth positively. The sensitivity, speed, and lowered cost per sample are some of the aspects that contribute to the increased adoption of NGS technology for research purposes.
Clinical Oncology Next Generation Sequencing Market Report Scope
| Report Attribute | Details |
| Market Size in 2024 | USD 907.36 million |
| Market Size by 2033 | USD 3,232.18 million |
| Growth Rate From 2024 to 2033 | CAGR of 15.16% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Technology, workflow, application, end use, region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd.; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E.; Qiagen N.V. |
Segments Insights:
Technology Insights
The targeted sequencing and resequencing segment held the largest market share of 73.17% in 2023 in terms of revenue, owing to the various benefits associated with this technology, such as decreased time, cost, and quantity of data analyzed during the tumor samples sequencing Furthermore, the clinical utility of targeted panels is increased due to their efficiency in detecting malignant tumors. According to a study published by the JCO Precision Oncology in September 2020, it was found that NGS panels are clinically helpful in 64% of cancer cases.
Whole-Genome Sequencing (WGS) is anticipated to be the fastest-growing segment with 17.5% CAGR from 2024 to 2032, owing to the usage of this technology to compare and differentiate tumor tissues from normal tissues. In addition, WGS of cancer patients enables the identification of treatments for current mutations, and aids target mutations in advance. This also supports analyzing cancer prognosis.
Workflow Insights
The NGS sequencing segment accounted for the largest revenue share of 57% in 2023 in workflow segment and it is expected to expand at the fastest CAGR over the forecast period. Sequencing includes the use of cutting-edge platforms and is a critical step of the complete workflow. The rise in cancer sequencing projects also expands segment growth. For instance, according to the study published by the National Library of Medicine in February 2020, the Pan-Cancer Analysis of Whole Genomes Consortium analyzed 38 cancer types by sequencing over 2,600 tumor samples.
NGS data analysis is expected to grow at a substantial rate. Efforts taken by key market players and scientists to invent advanced computational tools propel the segment growth. For instance, in May 2023, Researchers at the University of California, Los Angeles (UCLA) and the Children’s Hospital of Philadelphia (CHOP) invented a computational tool-Isoform peptide from RNA splicing for Immunotherapy target Screening (IRIS) capable of finding tumor antigens stemmed from alternative RNA splicing, extending the pool of cancer immunotherapy targets.
Application Insights
Screening held the largest market share of 81.9% in 2023, owing to the wide use of NGS in cancer screening programs across the world. Nowadays, NGS-based testing is considered the most efficient technique for identifying genetic alterations that can be targeted for clinical benefit in cancer patients. This technology enables clinicians to assess multiple gene alterations simultaneously.
The companion diagnostics segment is anticipated to witness the fastest CAGR of 20.9% from 2024 to 2033. Continuous product developments, partnerships & collaborations among the key participants are projected to increase the adoption of NGS for companion diagnostics.For instance, F. Hoffmann-La Roche Ltd expanded its partnership with Janssen Biotech Inc. (Janssen) in February 2023 to develop companion diagnostics for targeted treatments and to incorporate a broad range of companion diagnostics, comprising tissue and blood-based biomarkers, digital and sequencing pathology.
End-use Insights
The laboratories segment held the largest market share of 65.1% in 2023. Setting up complex workflows is a time-consuming process for laboratories. Therefore, most of the developed laboratories have created pre-existing workflows that are set according to standard procedures.
Moreover, with the enormous development and release of NGS assays for clinical purposes, detailed guidelines have been produced for NGS testing procedures. Thus, many FDA-approved tests come with specified standards, controls, and performance characteristics to verify the validity of the results. Several governing bodies in the U.S. regulate clinical laboratories. The CMS’s control laboratory testing via Clinical Laboratory Improvement Amendments (CLIA). These are also governed by state-level bodies that may have stricter regulations than CLIA. In addition, several organizations, such as the American College of Medical Genetics and Genomics (ACMG), the Association of Molecular Pathology (AMP), and the College of American Pathologists (CAP), have further developed the best guidelines for clinical laboratories.
As an end-user, clinics are anticipated to register the fastest CAGR of 18.1% from 2024 to 2033. Owing to the rising prevalence of cancer across the globe and increasing research and development activities in the market. According to the article published by JAMA Network in October 2020, next-generation sequencing has revolutionized over the past five years from research to clinical use. A minimum of 14 countries have undertaken initiatives to sequence large populations, and it is estimated that over 60 million people have their genomes sequenced by 2025. These statistics highlight the demand for the market over the forecast period.
Regional Insights
North America dominated the market in 2023 with a share of 49.68% owing to the measures taken by regulatory bodies to boost cancer screening diagnosis in the U.S., increasing R&D investment, and the presence of key players in the region.North America dominated the market in 2022 with a share of xx% owing to the measures taken by regulatory bodies to boost cancer screening diagnosis in the U.S., increasing R&D investment, and the presence of key players in the region. Key players in the region are focusing on technological advancements to strengthen the market position and provide the best solutions. For instance, Illumina Inc., a company of DNA sequencing and array-based technologies, introduced an artificial intelligence algorithm- PrimateAI-3D, in June 2023 that predicts disease-causing hereditary mutations in patients with unprecedented accuracy.
The Asia Pacific region is expected to expand at the fastest CAGR of 17.4% during 2024-2033 due to decreased sequencing costs, favorable government policies, rising R&D investments, and competitive pricing by key players. China has witnessed a huge drop in sequencing costs compared to earlier years. The prominent players in the country provide NGS services and products at a highly competitive price compared to other countries. Encouraging government policies and high investment by key market players are driving the market's growth.
Key Companies & Market Share Insights
Several small and mid-sized players are operating in the market. Companies involved in the market are adopting various strategies, such as the launch of innovative products, partnerships & collaborations, to maintain their market presence. For instance, in May 2023, Thermo Fisher Scientific collaborated with Pfizer to improve regional access to next-generation sequencing-based testing for breast and lung cancer patients in over 30 countries across Africa, the Middle East, Latin America, and Asia where developed genomic testing has earlier been confined or inaccessible. Some of the key players in the global clinical oncology next generation sequencing market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Clinical Oncology Next Generation Sequencing market.
By Technology
By Workflow
By Application
By End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers